Neuphoria Therapeutics Inc. (NEUP): Nasdaq/NYSE listing notice — Neuphoria Therapeutics regains Nasdaq compliance after holding 2025 annual meeting

Neuphoria Therapeutics Inc.

Received Nasdaq deficiency notice on July 18, 2025 for failing to hold annual meeting within 12 months of FY end (Rule 5620(a)).
Held 2025 annual shareholder meeting on December 12, 2025, satisfying the compliance requirement.
Nasdaq confirmed on December 18, 2025 that the company has regained compliance; matter is closed.
Previously disclosed delisting risk related to meeting requirement is now resolved.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Neuphoria Therapeutics Inc. received a nasdaq compliance regained notice regarding shareholders (rules 5620(a)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: shareholders
Rules: 5620(a)

Exact text from the filing

ompany was not in compliance with Nasdaq Listing Rule 5620(a) (the “ Listing Rule ”) as a result of the Company’s failure to hold a qualified annual meeting of stockholders within twelve months of the end of the Company’s fiscal year ended June

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Neuphoria Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-123289

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.